Cited 0 times in
Aggressive Surgical Excision of Supraclavicular Lymph Node Did Not Improve the Outcomes of Breast Cancer With Supraclavicular Lymph Node Involvement (KROG 16-14)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, K | - |
dc.contributor.author | Kim, SS | - |
dc.contributor.author | Shin, KH | - |
dc.contributor.author | Kim, JH | - |
dc.contributor.author | Ahn, SD | - |
dc.contributor.author | Choi, DH | - |
dc.contributor.author | Park, W | - |
dc.contributor.author | Lee, SY | - |
dc.contributor.author | Chun, M | - |
dc.contributor.author | Kim, JH | - |
dc.contributor.author | Kim, YB | - |
dc.contributor.author | Cha, J | - |
dc.contributor.author | Park, HJ | - |
dc.contributor.author | Lee, DS | - |
dc.contributor.author | Jung, W | - |
dc.date.accessioned | 2022-11-23T07:32:31Z | - |
dc.date.available | 2022-11-23T07:32:31Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 1526-8209 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/22759 | - |
dc.description.abstract | INTRODUCTION: The purpose of this study was to evaluate the outcomes of upfront surgery followed by radiation therapy (RT) for ipsilateral supraclavicular (SCN) and/or internal mammary (IMN) node-positive breast cancer. MATERIALS AND METHODS: One hundred fifty-eight patients were included; among these, 91 patients were SCN-positive, 54 were IMN-positive, and 13 were SCN- and IMN-positive. Patients underwent breast conserving surgery (n = 74) or mastectomy (n = 84) followed by systemic therapy, and adjuvant RT to whole breast/chest wall with or without regional nodal RT. Regarding regional treatments for SCN and IMN, SCN excision was performed in 59 (37.3%) patients, IMN excision in 10 (6.3%) patients, SCN RT in 143 (90.5%) patients, and IMN RT in 68 (43.0%) patients. RESULTS: The median duration of follow-up was 72 months (range, 7-182 months). There were 20 locoregional recurrences and 45 distant metastases. In-field failure was observed only in SCN (n = 8), and 6 of these patients initially underwent SCN excision. The 5-year locoregional recurrence-free survival, disease-free survival (DFS), and overall survival rates were 87.3%, 71.6%, and 89.7%, respectively. Neither SCN excision nor SCN RT dose >/= 54 Gy improved locoregional control (P = .927 and P = .693, respectively) or DFS (P = .394 and P = .686, respectively). Having >/= 10 involved axillary lymph nodes was the only independent prognosticator for DFS after adjusting for covariates (P = .003). CONCLUSION: Regional control rate in initially involved SCN and/or IMN was acceptable in patients treated with upfront surgery followed by systemic therapy plus adjuvant RT. More aggressive regional therapy such as SCN excision did not improve locoregional control or survival. | - |
dc.language.iso | en | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Breast | - |
dc.subject.MESH | Breast Neoplasms | - |
dc.subject.MESH | Chemoradiotherapy, Adjuvant | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lymph Node Excision | - |
dc.subject.MESH | Lymph Nodes | - |
dc.subject.MESH | Lymphatic Metastasis | - |
dc.subject.MESH | Mastectomy | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Recurrence, Local | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Survival Rate | - |
dc.title | Aggressive Surgical Excision of Supraclavicular Lymph Node Did Not Improve the Outcomes of Breast Cancer With Supraclavicular Lymph Node Involvement (KROG 16-14) | - |
dc.type | Article | - |
dc.identifier.pmid | 31629642 | - |
dc.subject.keyword | Internal mammary node | - |
dc.subject.keyword | Non-axillary regional lymph node | - |
dc.subject.keyword | Prognostic factors | - |
dc.subject.keyword | Radiation therapy | - |
dc.subject.keyword | Upfront surgery | - |
dc.contributor.affiliatedAuthor | Chun, M | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.1016/j.clbc.2019.09.004 | - |
dc.citation.title | Clinical breast cancer | - |
dc.citation.volume | 20 | - |
dc.citation.number | 1 | - |
dc.citation.date | 2020 | - |
dc.citation.startPage | 51 | - |
dc.citation.endPage | 60 | - |
dc.identifier.bibliographicCitation | Clinical breast cancer, 20(1). : 51-60, 2020 | - |
dc.embargo.liftdate | 9999-12-31 | - |
dc.embargo.terms | 9999-12-31 | - |
dc.identifier.eissn | 1938-0666 | - |
dc.relation.journalid | J015268209 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.